Cardiac	cardiac	O	O
Angiography	angiography	O	O
in	in	O	O
Renally	renally	O	B_disease
Impaired	impaired	O	I_disease
Patients	patients	O	O
(	(	O	O
CARE	care	O	O
)	)	O	O
study	study	O	O
:	:	O	O
a	a	O	O
randomized	randomized	O	O
double-blind	double-blind	O	O
trial	trial	O	O
of	of	O	O
contrast-induced	contrast-induced	O	O
nephropathy	nephropathy	O	S_disease
in	in	O	O
patients	patients	O	O
with	with	O	O
chronic	chronic	O	B_disease
kidney	kidney	O	B_disease
disease	disease	O	I_disease
.	.	O	O

BACKGROUND	background	O	O
:	:	O	O
No	no	O	O
direct	direct	O	O
comparisons	comparisons	O	O
exist	exist	O	O
of	of	O	O
the	the	O	O
renal	renal	O	O
tolerability	tolerability	O	O
of	of	O	O
the	the	O	O
low-osmolality	low-osmolality	O	O
contrast	contrast	O	O
medium	medium	O	O
iopamidol	iopamidol	S_chemical	O
with	with	O	O
that	that	O	O
of	of	O	O
the	the	O	O
iso-osmolality	iso-osmolality	O	O
contrast	contrast	O	O
medium	medium	O	O
iodixanol	iodixanol	S_chemical	O
in	in	O	O
high-risk	high-risk	O	O
patients	patients	O	O
.	.	O	O

METHODS	methods	O	O
AND	and	O	O
RESULTS	results	O	O
:	:	O	O
The	the	O	O
present	present	O	O
study	study	O	O
is	is	O	O
a	a	O	O
multicenter	multicenter	O	O
,	,	O	O
randomized	randomized	O	O
,	,	O	O
double-blind	double-blind	O	O
comparison	comparison	O	O
of	of	O	O
iopamidol	iopamidol	S_chemical	O
and	and	O	O
iodixanol	iodixanol	S_chemical	O
in	in	O	O
patients	patients	O	O
with	with	O	O
chronic	chronic	O	B_disease
kidney	kidney	O	B_disease
disease	disease	O	I_disease
(	(	O	O
estimated	estimated	O	O
glomerular	glomerular	O	O
filtration	filtration	O	O
rate	rate	O	O
,	,	O	O
20	20	O	O
to	to	O	O
59	59	O	O
mL/min	ml/min	O	O
)	)	O	O
who	who	O	O
underwent	underwent	O	O
cardiac	cardiac	O	O
angiography	angiography	O	O
or	or	O	O
percutaneous	percutaneous	O	O
coronary	coronary	O	O
interventions	interventions	O	O
.	.	O	O

Serum	serum	O	O
creatinine	creatinine	S_chemical	O
(	(	O	O
SCr	scr	S_chemical	O
)	)	O	O
levels	levels	O	O
and	and	O	O
estimated	estimated	O	O
glomerular	glomerular	O	O
filtration	filtration	O	O
rate	rate	O	O
were	were	O	O
assessed	assessed	O	O
at	at	O	O
baseline	baseline	O	O
and	and	O	O
2	2	O	O
to	to	O	O
5	5	O	O
days	days	O	O
after	after	O	O
receiving	receiving	O	O
medications	medications	O	O
.	.	O	O

The	the	O	O
primary	primary	O	O
outcome	outcome	O	O
was	was	O	O
a	a	O	O
postdose	postdose	O	O
SCr	scr	S_chemical	O
increase	increase	O	O
>	>	O	O
or	or	O	O
=	=	O	O
0.5	0.5	O	O
mg/dL	mg/dl	O	O
(	(	O	O
44.2	44.2	O	O
micromol/L	micromol/l	O	O
)	)	O	O
over	over	O	O
baseline	baseline	O	O
.	.	O	O

Secondary	secondary	O	O
outcomes	outcomes	O	O
were	were	O	O
a	a	O	O
postdose	postdose	O	O
SCr	scr	S_chemical	O
increase	increase	O	O
>	>	O	O
or	or	O	O
=	=	O	O
25	25	O	O
%	%	O	O
,	,	O	O
a	a	O	O
postdose	postdose	O	O
estimated	estimated	O	O
glomerular	glomerular	O	O
filtration	filtration	O	O
rate	rate	O	O
decrease	decrease	O	O
of	of	O	O
>	>	O	O
or	or	O	O
=	=	O	O
25	25	O	O
%	%	O	O
,	,	O	O
and	and	O	O
the	the	O	O
mean	mean	O	O
peak	peak	O	O
change	change	O	O
in	in	O	O
SCr	scr	S_chemical	O
.	.	O	O

In	in	O	O
414	414	O	O
patients	patients	O	O
,	,	O	O
contrast	contrast	O	O
volume	volume	O	O
,	,	O	O
presence	presence	O	O
of	of	O	O
diabetes	diabetes	O	B_disease
mellitus	mellitus	O	I_disease
,	,	O	O
use	use	O	O
of	of	O	O
N-acetylcysteine	n-acetylcysteine	S_chemical	O
,	,	O	O
mean	mean	O	O
baseline	baseline	O	O
SCr	scr	S_chemical	O
,	,	O	O
and	and	O	O
estimated	estimated	O	O
glomerular	glomerular	O	O
filtration	filtration	O	O
rate	rate	O	O
were	were	O	O
comparable	comparable	O	O
in	in	O	O
the	the	O	O
2	2	O	O
groups	groups	O	O
.	.	O	O

SCr	scr	S_chemical	O
increases	increases	O	O
>	>	O	O
or	or	O	O
=	=	O	O
0.5	0.5	O	O
mg/dL	mg/dl	O	O
occurred	occurred	O	O
in	in	O	O
4.4	4.4	O	O
%	%	O	O
(	(	O	O
9	9	O	O
of	of	O	O
204	204	O	O
patients	patients	O	O
)	)	O	O
after	after	O	O
iopamidol	iopamidol	S_chemical	O
and	and	O	O
6.7	6.7	O	O
%	%	O	O
(	(	O	O
14	14	O	O
of	of	O	O
210	210	O	O
patients	patients	O	O
)	)	O	O
after	after	O	O
iodixanol	iodixanol	S_chemical	O
(	(	O	O
P=0.39	p=0.39	O	O
)	)	O	O
,	,	O	O
whereas	whereas	O	O
rates	rates	O	O
of	of	O	O
SCr	scr	S_chemical	O
increases	increases	O	O
>	>	O	O
or	or	O	O
=	=	O	O
25	25	O	O
%	%	O	O
were	were	O	O
9.8	9.8	O	O
%	%	O	O
and	and	O	O
12.4	12.4	O	O
%	%	O	O
,	,	O	O
respectively	respectively	O	O
(	(	O	O
P=0.44	p=0.44	O	O
)	)	O	O
.	.	O	O

In	in	O	O
patients	patients	O	O
with	with	O	O
diabetes	diabetes	O	S_disease
,	,	O	O
SCr	scr	S_chemical	O
increases	increases	O	O
>	>	O	O
or	or	O	O
=	=	O	O
0.5	0.5	O	O
mg/dL	mg/dl	O	O
were	were	O	O
5.1	5.1	O	O
%	%	O	O
(	(	O	O
4	4	O	O
of	of	O	O
78	78	O	O
patients	patients	O	O
)	)	O	O
with	with	O	O
iopamidol	iopamidol	S_chemical	O
and	and	O	O
13.0	13.0	O	O
%	%	O	O
(	(	O	O
12	12	O	O
of	of	O	O
92	92	O	O
patients	patients	O	O
)	)	O	O
with	with	O	O
iodixanol	iodixanol	S_chemical	O
(	(	O	O
P=0.11	p=0.11	O	O
)	)	O	O
,	,	O	O
whereas	whereas	O	O
SCr	scr	S_chemical	O
increases	increases	O	O
>	>	O	O
or	or	O	O
=	=	O	O
25	25	O	O
%	%	O	O
were	were	O	O
10.3	10.3	O	O
%	%	O	O
and	and	O	O
15.2	15.2	O	O
%	%	O	O
,	,	O	O
respectively	respectively	O	O
(	(	O	O
P=0.37	p=0.37	O	O
)	)	O	O
.	.	O	O

Mean	mean	O	O
post-SCr	post-scr	O	O
increases	increases	O	O
were	were	O	O
significantly	significantly	O	O
less	less	O	O
with	with	O	O
iopamidol	iopamidol	S_chemical	O
(	(	O	O
all	all	O	O
patients	patients	O	O
:	:	O	O
0.07	0.07	O	O
versus	versus	O	O
0.12	0.12	O	O
mg/dL	mg/dl	O	O
,	,	O	O
6.2	6.2	O	O
versus	versus	O	O
10.6	10.6	O	O
micromol/L	micromol/l	O	O
,	,	O	O
P=0.03	p=0.03	O	O
;	;	O	O
patients	patients	O	O
with	with	O	O
diabetes	diabetes	O	S_disease
:	:	O	O
0.07	0.07	O	O
versus	versus	O	O
0.16	0.16	O	O
mg/dL	mg/dl	O	O
,	,	O	O
6.2	6.2	O	O
versus	versus	O	O
14.1	14.1	O	O
micromol/L	micromol/l	O	O
,	,	O	O
P=0.01	p=0.01	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
The	the	O	O
rate	rate	O	O
of	of	O	O
contrast-induced	contrast-induced	O	O
nephropathy	nephropathy	O	S_disease
,	,	O	O
defined	defined	O	O
by	by	O	O
multiple	multiple	O	O
end	end	O	O
points	points	O	O
,	,	O	O
is	is	O	O
not	not	O	O
statistically	statistically	O	O
different	different	O	O
after	after	O	O
the	the	O	O
intraarterial	intraarterial	O	O
administration	administration	O	O
of	of	O	O
iopamidol	iopamidol	S_chemical	O
or	or	O	O
iodixanol	iodixanol	S_chemical	O
to	to	O	O
high-risk	high-risk	O	O
patients	patients	O	O
,	,	O	O
with	with	O	O
or	or	O	O
without	without	O	O
diabetes	diabetes	O	B_disease
mellitus	mellitus	O	I_disease
.	.	O	O

Any	any	O	O
true	true	O	O
difference	difference	O	O
between	between	O	O
the	the	O	O
agents	agents	O	O
is	is	O	O
small	small	O	O
and	and	O	O
not	not	O	O
likely	likely	O	O
to	to	O	O
be	be	O	O
clinically	clinically	O	B_disease
significant	significant	O	I_disease
.	.	O	O

